BD Sees Bright Future For Edwards’ Critical Care, Now BD Advanced Patient Monitoring

Edwards Lifesciences’ Critical Care business “invented the hemodynamic monitoring category, and its solutions are currently used in more than 10,000 hospitals globally to better understand the cardiovascular condition in real-time for critically ill patients, which helps improve outcomes,” says BD, which sees synergies and new innovation opportunities across the groups’ data sets and platforms. Acquired for $4.2bn cash, Critical Care generated more than $900m in revenue in 2023.

• Source: Shutterstock

“I see a big opportunity around AI and smart connected care,” Becton Dickinson AB executive vice president and chief technology officer Beth McCombs told Medtech Insight in March, three months before the global medtech announced it would acquire Edwards Lifesciences Corp.’ Critical Care business.

BD reported on 3 September its completion of the $4.2bn cash deal, which it says will put BD “at the...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Deals

Investor Eye: Intuitive Surgical Hops, Skips, And Jumps Into VC

 

When a large medtech company sets up a venture fund, it typically invests in technologies that are adjacent to its pre-existing portfolio. Intuitive Surgical’s approach is different.

test carousel-Medtech

 
• By 

test carousel-Medtech

MI-Business (Free-2): Prison Is the First Mental Health Visit for Many in Spain

 
• By 

Spain has one of the highest incarceration rates in Europe, with 160 individuals imprisoned per 100,000 residents. In 2020, 43,494 people were incarcerated in facilities not managed by regional health authorities — essentially all regions except Catalonia, the Basque Country, and Navarra.

Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

 

Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

More from Business

test carousel-Medtech

 
• By 

test carousel-Medtech

test carousel

 
• By 

test carousel-HBW

News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards

This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.